Amiloidózis: vizsgálatok itt: Kína
38 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1. fázisTaking peopleStudy of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
- Where
- Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
- Életkor
- 18 év and over
- People
- 12
- Run by
- Gracell Biotechnologies (Shanghai) Co., Ltd.
See details and how to joinNCT07250269 - 3. fázisTaking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Beijing, Binhai, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Liaoning, Nanchang, Nanjing, Shanghai, Shanghaishi, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 1280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - 3. fázisTaking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou, Hefei, Hexi District, Jinan, Nanchang, Nangang, Nanjing, Shenzhen Shi, Taiyuan, Wuhan, Xicheng, Yuanjiagang
- Életkor
- 18 év to 85 év
- People
- 1750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - No phaseTaking peopleNon-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- Where
- Beijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Shaanxi, Shanghai, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Xiamen
- Életkor
- 18 év to 130 év
- People
- 1850 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06465810 - 1/2. fázisNot yet taking people in Kína[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 48
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07835880 - 2. fázisTaking peopleBeta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 60
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07829705 - No phaseTaking peopleA Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
- Where
- Beijing
- People
- 2000
- Run by
- Peking University First Hospital
See details and how to joinNCT05283993 - No phaseTaking peopleA Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- Peking University First Hospital
See details and how to joinNCT07215494 - No phaseTaking peopleLong-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07654855 - No phaseCsak meghívásosMultimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
- Where
- Beijing
- People
- 49
- Run by
- Beijing Anzhen Hospital
See details and how to joinNCT07103863 - No phaseTaking peopleOverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Wuhan
- People
- 52 121 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06355934 - No phaseTaking peoplePan-Amyloid PET/CT in Various Amyloid-Related Disease
- Where
- Hefei, Qingdao, Tianjin
- Életkor
- 18 év to 80 év
- People
- 500
- Run by
- Tianjin Medical University
See details and how to joinNCT07130565 - No phaseTaking people[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
- Where
- Hefei, Qingdao, Tianjin
- Életkor
- 18 év and over
- People
- 25
- Run by
- Tianjin Medical University
See details and how to joinNCT07232459 - 3. fázisNot yet taking people in KínaAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Beijing, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Tianjin, Wuhan, Xi'an
- People
- 1180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - 1/2. fázisNot yet taking people in KínaA Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
- Where
- Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Shanghai, Wuhan, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
See details and how to joinNCT07765524 - 2. fázisNot yet taking people in KínaBCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 20
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07751471 - 2. fázisTaking peopleA Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07638683 - 2. fázisTaking peopleSonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
- Where
- Beijing, Xi’an
- Életkor
- 18 év and over
- People
- 39
- Run by
- Peking University People's Hospital
See details and how to joinNCT07335887 - 2. fázisTaking peopleBCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 21
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07151690 - No phaseTaking peopleOptimize First-line Treatment for AL Amyloidosis With t (11; 14)
- Where
- Beijing, Nanjing, Qingdao, Xi’an
- People
- 41
- Run by
- Jin Lu, MD
See details and how to joinNCT06192979 - 1/2. fázisNot yet taking people in KínaSonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07687004 - 1/2. fázisTaking peopleAssessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
- Where
- Anyang, Baoding, Beijing, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Nanjing, Qingdao, Shanghai, Shenyang, Shenzhen, Tianjin, Xi’an, Zhengzhou
- Életkor
- 18 év to 80 év
- People
- 70
- Run by
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT07266116 - No phaseTaking peopleRapid dFLC Response Predict CHR in AL Amyloidosis
- Where
- Beijing, Harbin, Nanjing, Shenyang, Xi’an
- Életkor
- 18 év to 99 év
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT06627309 - 3. fázisTaking peopleA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 90
- Run by
- Sinocelltech Ltd.
See details and how to joinNCT07388602 - No phaseTaking peoplePrecision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques
- Where
- Beijing
- People
- 1000
- Run by
- Chinese Academy of Medical Sciences, Fuwai Hospital
See details and how to joinNCT07336394